Peculiarities of drug therapy of lower extremities chronic venous insufficiency
Abstract
Chronic vein diseases (CVD) depending on the design and evaluation criteria of conducted epidemiologic studies are diagnosed in 20-85% of adult residents of industrially developed countries. Meanwhile only due to appearance of the unified international classification CEAP it has become possible to reliably estimate the frequency and structure of CVD in various countries of the world. Moreover, implementation of СЕАР in the routine clinical practice determined the necessity of unification of terminology used with respect to CVD and their manifestations. In particular, clear definitions of notions "chronic vein diseases (CVD)" and "chronic venous insufficiency (CVI)". In the first case the matter at issue is all - functional as well as pathomorphologic - CVD manifestations. CVI is issued to designate graver forms of the disease accompanied by objective signs of venous macrohemodynamics disturbances. In other words, the diagnosis "chronic venous insufficiency" can be used with respect to patients with C3 (chronic venous edema) - С (active trophic ulcer) of the СЕАР clinical class [1, 2].
About the Authors
V. Y. Bogachev
Pirogov Russian Scientific and Research Medical University
Russian Federation
Russian Federation
B. V. Boldin
Pirogov Russian Scientific and Research Medical University
Russian Federation
Russian Federation
O. V. Dzhenina
First Phlebologic Center
Russian Federation
Russian Federation
V. N. Lobanov
First Phlebologic Center
Russian Federation
Russian Federation
References
1. EkLof B, Perrin M, Delis K, Rutherford R. Update terminology of chronic venous disorders: the Vein Term Transatlantic Interdisciplinary Consensus Document. J Vasc Surg, 2009, 21: 498-501.
2. Perrin M. Description and definition of venous symptoms in chronic venous disorders: a review. Medicographia, 2015, 37(1): 10-15.
3. Rabe E, Guex J-J, Puskas A, Scuderi A, Fernandez Quesada F. The VCP Coordinators Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. IntAngiol, 2012, 31(2): 105-115.
4. Савельев В.С., Кириенко А.И., Богачев В.Ю. Хронические заболевания вен в Российской Федерации. Результаты международной исследовательской программы VEIN CONSULT. Флебология, 2010, 4(3): 9-12.
5. Bergan J, Schmid-Schonbein G, Coleridge-Smith P, Nicolaides A, Boisseau M, Eklof B. Chronic venous disease. N Engl J Med, 2006, 355: 488-498.
6. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология, 2013, 7(2): 2-47.
7. Nicolaides A, Kakkos S, Eklof D, Perrin V, Nelzen O, Neglen P, Partsch H, Rybak Z. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol, 2014, 33(2): 87-208.
8. Wittens C, Davies AH, Blbkgaard N et al. Management of Chronic Venous Disease Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2015, 49: 678737.
9. Богачев В.Ю., Голованова О.В., Кузнецов А.Н. Особенности лечения хронических заболеваний вен в России. Предварительные результаты программы VEIN ACT. Ангиология и сосудистая хирургия, 2015, 21(2): 76-82.
10. Barwell JR, Davies CE, Deacon J, Harvey K, Minor J, Sassano A et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet, 2004 Jun 5, 363(9424): 1854-1859.
11. Духанин А.С. Системные флебопротекторные препараты: от активного вещества к клиническому эффекту. Ангиология и сосудистая хирургия, 2014, 20(4): 84-92.
12. Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capella D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev, 2005. CD003229.
13. Богачев В.Ю., Голованова О.В., Кузнецов А.Н., Шекоян А.О. Био-флавоноиды и их значение в ангиологии. Фокус на диосмин. Ангиология и сосудистая хирургия, 2013, 19(3): 75-82.
14. Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol, 2008 Feb, 27(1): 81-5.
15. Богачев В.Ю., Голованова О.В., Кузнецов А.Н. Хронический венозный отек (С3 по СЕАР): Новые международные рекомендации и консенсусы. Ангиология и сосудистая хирургия, 2013, 19(3): 7582.
16. Cornu Thenard A, Scuderi A, Ramelet AA et al. UIP 2011 C3 Consensus. Int Angiol, 2012, 31(5): 414-419.
17. Stout N, Partsch H, Szolnoky G et al. Chronic edema of the lower extremities: international consensus recommendations for compression therapy clinical research trials. Int Angiol, 2012, 31(4): 316-329.
18. Allaert F-A. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol, 2012, 31(4): 310-315.
19. Perrin M, Ramelet A-A. Pharmacological Treatment of Primary Chronic Venous Disease: Rationale, Results and Unanswered Questions. Eur J Vasc Endovasc Surg, 2011, 41: 117-125.
20. Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol, 2015, 34: 428-436.
21. Maggioli A. Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction. Phlebolymphology, 2016, 23(2): 82-91.
22. Varatharajan L, Thapar A, Lane T, Munster A, Davies A. Pharmacological adjuncts for chronic venous ulcer healing: a systematic review. Phlebology, 2016, 31(5): 356-365. Coleridge-Smith P, Lok C, Ramelet A-A. Venous Leg Ulcer: A Meta-analysis of Adjunctive Therapy with Micronized Purified Flavonoid Fraction. Eur J Vasc Endovasc Surg, 2005, 30: 198-208.
Review
For citations:
Bogachev V.Y., Boldin B.V., Dzhenina O.V., Lobanov V.N. Peculiarities of drug therapy of lower extremities chronic venous insufficiency. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2016;(3-4):11-15. (In Russ.)
Views:
763
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 